NanoSphere Health Sciences Announces Retirement of CEO Robert E. Sutton; Dr. Mark Percival Named As Successor
Colorado Passes Law Allowing Doctors to Prescribe Cannabis in Place of Opioids
NanoSphere Board Unanimously Selects Dr. Percival As New CEO
Vancouver, June 10, 2019 (GLOBE NEWSWIRE) -- (June 10, 2019) – NanoSphere Health Sciences INC (NSHS.CN) (NSHSF), is delighted to announce that the board of directors has appointed Dr. Mark Percival to lead the company as CEO, succeeding Robert E. Sutton who is retiring.
NanoSphere and Vertical Unveil the Future of Cannabis at Hall of Flowers Trade Show
Denver-based NanoSphere Health Sciences Offers Alternative Cannabis Medication to Help Replace Opioids for Patients Suffering from Chronic Pain
DENVER (DATE)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) CEO Robert Sutton today congratulated the Governor and Legislature of Colorado for their passage of an historic bill allowing physicians to recommend cannabis instead of opioids for relief of pain.
NanoSphere Health Sciences Has Received Notice of Allowance for a Patent for its Breakthrough Nanoparticle Encapsulations of NSAIDs
Award-Winning Evolve Formulas Transdermal NanoSerum™ Has Hit Dispensary Shelves in the Golden State
DENVER (DATE)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (‘NanoSphere or ‘the Company’) parent company of cannabis brand Evolve Formulas, in partnership with Vertical™, the largest fully integrated company in the legal medical cannabis industry, will formally unveil the Evolve Formulas line for the California market at the Hall of Flowers trade show on April 30.
Canada Prepares To Legalize Marijuana Edibles Market
Allowance for the patent marks significant advancement for the treatment of pain and inflammation
Denver (April 24, 2019) – Biotechnology leader NanoSphere Health Sciences, LLC (CSE: NSHS) (OTC: NSHSF) has received formal Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Application 2,970,91, covering “The Method of Treating Inflammatory Disorders and Global Inflammation with Phospholipid Nanoparticle Encapsulations of NSAIDs.”
New Cannabis Delivery System, City News
Canadians could have low-dose, individually packaged cannabis infused food and drinks by summer.
By Mike Adams, CannabisNow
NanoSphere Products Approved for Sale in California Cannabis Market
Cannabis products using nanotechnology with greater THC and CBD bioavailability are being produced right here in Winnipeg. You don’t have to smoke, vape, or eat the cannabis products to get THE high–the nano-sized cannabis particles simply pass through your skin and into your blood stream.
NanoSphere Developing Production Lab at Delta 9 Cannabis
Vancouver (April 2, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce its Evolve cannabis products will be available for purchase in California for the first time, after receiving final approval by the State of California.
NanoSphere’s Evolve Formula NanoSerum™ is expected to hit store shelves in the Los Angeles area by April 8th.
NanoSphere Closes $2million Private Placement Offering
- NanoSphere’s First Canadian Products Scheduled for Initial Production in April -
VANCOUVER (MARCH 7, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“NanoSphere” or the Company) is pleased to announce work has begun on the production facility for NanoSphere’s products in Canada, based at the Delta 9 Cannabis Inc. (TSXV: NINE) (OTC: VRNDF) facility in Winnipeg, Manitoba.
NanoSphere Signs Definitive Licensing Agreement in Oregon
DENVER (February 21, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“Nanosphere” or “the Company”) is pleased to announce that it has closed its second and final tranche of its non-brokered private placement announced on Feb. 11, 2019. Pursuant to the first tranche, the company issued 6,666,394 units at a price of 30 cents per unit for gross proceeds of $1,999,918.20.
NanoSphere Opens $2 million Private Placement Offering
Partnership with Cascade Pure Brings Disruptive Evolve Formulas Technology to $550 Million Oregon Cannabis Market
DENVER (Feb. 20, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“NanoSphere” or “the Company”) is pleased to announce the signing of a definitive Licensing Agreement with Oregon cannabis company Cascade Pure, LLC. The Agreement gives Cascade Pure the exclusive right to produce and distribute Evolve Formulas products in the State of Oregon.
The Cannabis Company That Really DELIVERS
DENVER--(BUSINESS WIRE)--NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“Nanosphere” or “the Company”) is pleased to announce that it will conclude a private placement of up to CAD$2,000,000, which will incorporate the balance of the financing announced on November 16, 2018 as updated December 17, 2018.
NanoSphere Signs Definitive Licensing Agreement with Delta 9 Cannabis Inc.
As the cannabis industry matures, both the opportunities and the challenges in this new sector are starting to crystallize. But what is a “challenge” for the cannabis industry as a whole can spell opportunity for individual companies. Perhaps no niche of the industry illustrates this point better than cannabis delivery technology.
Is the Fountain of Youth Found in Nanoparticles?
Vancouver, BC (January 24, 2019) – NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce the Company has signed a Definitive Master Licensing Agreement (the Agreement) with Delta 9 Cannabis Inc. (TSXV: NINE) (OTC: VRNDF) (Delta 9) in a deal that opens the Canadian market to NanoSphere’s patented groundbreaking delivery technology.
NanoSphere Partners with Gofire to Debut DoseCode-Enabled Products in Colorado Market
—NanoSphere Announces Anti-Aging Product Using Nano-Sized Particles of Hyaluronic Acid—
DENVER (January 17, 2019) – NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) announced today it has developed an anti-aging product combining Hyaluronic Acid (HA) with the Company’s patented Nanosphere Delivery System™.
Nanosphere Closes $1.335m First Tranche of Private Placement
—Scannable Technology Grants Patients Access to Descriptions, Reviews and Dosing Information for Evolve Formulas Products—
DENVER (December 6, 2018) – NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, today announced the launch of its new, DoseCode-enabled Evolve Formulas products in the Colorado market, leveraging industry-first technology from Denver-based healthcare startup Gofire.
NanoSphere Develops New Product Eliminating Need to Smoke Cannabis
DENVER (December 14, 2018) – NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce a first tranche closing of its non-brokered private placement announced November 28, 2018. Pursuant to the first tranche, the company issued 4,452,254 Units at a price of $0.30 per Unit for gross proceeds of CAD $1,335,676.
NanoSphere Announces Revised Terms for Private Placement
DENVER--(November 26, 2018)--NanoSphere Health Sciences Inc. (CSE:NSHS) (OTC:NSHSF) is pleased to announce the Company has developed a new intraoral delivered cannabis product for the Canadian market, which produces similar effects to smoking cannabis, but is safer and more effective than edibles.
Nanosphere Announces $2.25 Million Financing for Rapid Expansion of Cannabis Product Line
DENVER--(BUSINESS WIRE)--NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) announces revised terms for its non-brokered private placement previously announced on Nov. 16, 2018. The offering will consist of up to 7,500,000 units at a price of $0.30 per unit for gross proceeds of up to CAD $2,250,000. Each unit will be comprised of a common share and a full purchase warrant exercisable to purchase a further common share at a price of $0.50 cents for a period of 24 months, subject to accelerated expiry if the Company’s shares trade at or above $0.75 for 15 consecutive days.
DENVER (November 16, 2018)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce a non-brokered private placement of up to CAD $2,250,000. The proceeds will be used to expand our award-winning Evolve Formulas cannabis products into more markets in the US, Canada, and outside of North America. Funds will also be used to develop new products, increase production in the states that Evolve Products are available in, as well as for general working capital.